Compelling evidence have shown an association between BARD1 mutations and breast and/or ovarian cancer susceptibility; consequently, BARD1 is now included in panels of clinical genes testing for cancer susceptibility [41]. This evidence concerns the gene BARD1 and ovarian cancer.